Cargando…

Luspatercept in Low-Risk Myelodysplastic Syndrome: A Real-World Single Institution Case Series

Detalles Bibliográficos
Autores principales:	Khan, Shamis, Alam, Sara Taveras, Ramos, Rosa Torres, Mbue, John Etumbani, Apostolidou, Effrosyni, Rivero, Gustavo A., Yellapragada, Sarvari Venkata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763517/ https://www.ncbi.nlm.nih.gov/pubmed/35997953 http://dx.doi.org/10.1007/s44228-022-00016-4

Ejemplares similares

Pulmonary Complications of Azanucleoside Therapy in Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia
por: Molina, Manuel, et al.
Publicado: (2015)

Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes
por: Tinsley-Vance, Sara M., et al.
Publicado: (2023)

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
por: Komrokji, Rami S., et al.
Publicado: (2022)

Progressive transfusion and growth factor independence with adjuvant sertraline in low risk myelodysplastic syndrome treated with an erythropoiesis stimulating agent and granulocyte-colony stimulating factor
por: Nautiyal, Kirtan, et al.
Publicado: (2014)

An eye‐catching atypical illustration of the evaluation and management of AL amyloidosis secondary to myeloma
por: Khan, Shamis, et al.
Publicado: (2021)

Luspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen-deficiency in mice
por: Weidner, Heike, et al.
Publicado: (2022)

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes
por: Komrokji, Rami S., et al.
Publicado: (2023)

Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept
por: Delanghe, Sigurd, et al.
Publicado: (2022)

Population Pharmacokinetics and Exposure–Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes
por: Chen, Nianhang, et al.
Publicado: (2020)

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts
por: Zeidan, Amer M., et al.
Publicado: (2022)

Disparities in mortality among acute myeloid leukemia‐related hospitalizations
por: Alam, Sara Taveras, et al.
Publicado: (2022)

Luspatercept: A New Tool for the Treatment of Anemia Related to β-Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis
por: Hatzimichael, Eleftheria, et al.
Publicado: (2022)

Elderly Hemopoietic and Inflammatory Signature for Life-Threatening COVID-19 Infection
por: Romero, Jesus, et al.
Publicado: (2020)

Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial
por: Oliva, Esther Natalie, et al.
Publicado: (2021)

Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study
por: Platzbecker, Uwe, et al.
Publicado: (2022)

P697: DISTINCT SPLICING ALTERATIONS ASSOCIATED WITH CLINICAL RESPONSE TO LUSPATERCEPT IN PATIENTS WITH LOWER‑RISK MYELODYSPLASTIC SYNDROMES FROM THE MEDALIST STUDY
por: Aluri, Srinivas, et al.
Publicado: (2023)

P1506: REAL-WORLD DATA ON THE USE OF LUSPATERCEPT IN GREEK PATIENTS WITH TRANSFUSION DEPENDENT THALASSEMIA
por: Delaporta, P., et al.
Publicado: (2022)

P733: TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RECEIVING LUSPATERCEPT IN ROUTINE CLINICAL PRACTICE IN THE UNITED STATES
por: Mukherjee, Sudipto, et al.
Publicado: (2023)

Luspatercept‐induced reduction in transfusion requirement in α‐thalassemia
por: Jackson, Nicholas, et al.
Publicado: (2020)

Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts
por: Platzbecker, Uwe, et al.
Publicado: (2023)

Luspatercept for transfusion-dependent β-thalassemia: time to get real
por: Musallam, Khaled M., et al.
Publicado: (2023)

The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia
por: Delgado, Julio, et al.
Publicado: (2021)

Kaposi Sarcoma Revealing a Myelodysplastic Syndrome
por: Jouini, Wafa, et al.
Publicado: (2022)

The importance of critically short telomere in myelodysplastic syndrome
por: Shin, Dong-Yeop, et al.
Publicado: (2022)

Challenges and solutions for instituting an efficient maintenance program for laboratory equipment in Central Asian, and developing world, countries
por: Ikranbegiin, Riza, et al.
Publicado: (2019)

Efficacy and Safety of Luspatercept in the Treatment of β-Thalassemia: A Systematic Review
por: Dighriri, Ibrahim M, et al.
Publicado: (2022)

Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence
por: Longo, Filomena, et al.
Publicado: (2023)

Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts
por: Martín, Iván, et al.
Publicado: (2017)

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
por: Liapis, Konstantinos, et al.
Publicado: (2021)

Erythrodermic Leukemia Cutis in Patient with Myelodysplastic Syndrome with Multilineage Dysplasia
por: Viviani, Filippo, et al.
Publicado: (2022)

Primary bone lymphoma of the ilium successfully treated without radiation
por: Nguyen, Charles B., et al.
Publicado: (2020)

Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia
por: Piga, Antonio, et al.
Publicado: (2022)

Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article
por: Hussain, Munawwar, et al.
Publicado: (2023)

Myelodysplastic syndromes are multiclonal diseases derived from hematopoietic stem and progenitor cells
por: Luo, Bingqing, et al.
Publicado: (2022)

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
por: Komrokji, Rami S., et al.
Publicado: (2022)

Prognostic landscape of mitochondrial genome in myelodysplastic syndrome after stem-cell transplantation
por: Dong, Jing, et al.
Publicado: (2023)

Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome
por: Al-Kali, Aref, et al.
Publicado: (2023)

Common cardiovascular biomarkers can independently predict outcome of patients with Myelodysplastic syndromes
por: Mitroulis, Ioannis, et al.
Publicado: (2023)

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2021)

Detection of erythropoiesis stimulating agent Luspatercept after administration to healthy volunteers for antidoping purposes
por: Marchand, Alexandre, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ingg3p341t4mrusqq15h66fo7p